CClinicalTrials.gg
RecruitingNCT04240522ProRaDUpdated Feb 5, 2026

Prospective Longitudinal Observational Research in Atopic Dermatitis

An observational study in Atopic Dermatitis, Asthma and Atopic Dermatitis and Related Conditions, sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 1 Year to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by University of Zurich · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
1 Year to 85 Years
Sex
All
01

Study summary

Atopic dermatitis (AD) is a frequent chronic relapsing inflammatory skin disorder, characterized by intensely itchy eczema. AD usually starts within the first 2 years of life. In 30 - 60% of children, inflammation spreads onto other body surfaces such as the gastrointestinal tract, the respiratory tract, and the conjunctives within a few years. This sequence is called atopic march.

Atopic dermatitis and associated atopic diseases are more frequent in families, suggesting a genetic predisposition. However, the underlying factors such as genetic phenotype, environmental factors, or life style which cause or worsen an existing allergic disease are not understood yet. Affected people suffer from recurrent flares that result in significantly impaired quality.

This study will collect clinical and laboratory data to elucidate immunotolerance and preventiv stategies with the aim to develop new and individual treatment options of atopic diseases.

Read the detailed description

Primary Objetive:

In the planned project, the main objective is to identify endogenous (e.g. immunological and molecular factors) and exogenous factors (e.g. environmental, socioeconomic and microbial factors) that influence the course and remission of AD. More specifically to identify factors that are significantly different between patients that have or do not have remission from AD.

Secondary Objective:

(i) To identify endogenous and exogenous factors such as immunological, molecular and microbial factors to separate subgroups of patients (endotypes) with distinct local and systemic inflammatory responses.

(ii) To identify potential biomarkers predicting the individual clinical course of AD and other atopic diseases including asthma, food allergy and allergic rhinitis.

02

Conditions studied

  • Atopic Dermatitis
  • Asthma
  • Atopic Dermatitis and Related Conditions

Keywords

  • Eczema
  • Dermatitis
  • Atopy
03

Who can participate

Ages eligible
1 Year to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All patients with atopic dermatits, any other allergic diseases and /or healthy controls

Inclusion criteria

  • Age 0 - 85 years
  • Diagnosis of AD and/or another disease of the atopic group (i.e. allergic rhinitis, allergic asthma, food allergy)
  • The inclusion of patients in this study is independent from the current therapy. During the study all patients will be kept on a therapy that is medically indicated

The inclusion criteria for healthy controls in this study are as follows:

  • Age 0 - 85 years
  • No diagnosis or history of allergic disease
  • The inclusion of patients in this study is independent from the current therapy. During the study all patients will be kept on a therapy that is medically indicated

Written consent will be obtained after detailed information of the study was given to the participant.

Exclusion criteria

Exclusion Criteria

- Unable to give consent or refusal to participate in the study

04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
05

What researchers measure

Primary outcomes

  1. Remission of atopic dermatitis and associated allergic diseases

    Prospective observational study

    Time frame: 5 years

Secondary outcomes

  1. Endogenous and exgogenouse factors that influence and predict the course of AD.

    Prospective observational study

    Time frame: 5 years

  2. Identification of potential biomarkers predicting the course of AD

    Prospective observational study

    Time frame: 5 years

06

Study locations

1 of 1 sites recruiting
  • Allergy Unit, Dept. of Dermatology, Unviersity Hosptial of Zurich
    Zurich, Canton of Zurich 8091, Switzerland
    • Marie-Charlotte Brueggen, Prof, MD · Contact · prorad@usz.ch · +41 43 253 10 75
    Recruiting
07

Registry details

Key details

Study ID
NCT04240522
Lead sponsor
University of Zurich
Collaborators
University of Bonn
Responsible party
Sponsor
First posted
Jan 27, 2020
Start date
Apr 4, 2017
Primary completion
Mar 30, 2031 (estimated)
Completion
Mar 30, 2031 (estimated)
Last update
Feb 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion